2.30
-0.13(-5.35%)
Currency In USD
| Previous Close | 2.43 |
| Open | 2.38 |
| Day High | 2.49 |
| Day Low | 2.27 |
| 52-Week High | 2.85 |
| 52-Week Low | 0.49 |
| Volume | 609,627 |
| Average Volume | 1.46M |
| Market Cap | 211.32M |
| PE | -9.58 |
| EPS | -0.24 |
| Moving Average 50 Days | 1.64 |
| Moving Average 200 Days | 1.07 |
| Change | -0.13 |
If you invested $1000 in Context Therapeutics Inc. (CNTX) since IPO date, it would be worth $450.98 as of February 14, 2026 at a share price of $2.3. Whereas If you bought $1000 worth of Context Therapeutics Inc. (CNTX) shares 3 years ago, it would be worth $2,765.75 as of February 14, 2026 at a share price of $2.3.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting
GlobeNewswire Inc.
Nov 07, 2025 12:30 PM GMT
PHILADELPHIA, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today shared
Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
GlobeNewswire Inc.
Oct 06, 2025 11:30 AM GMT
PHILADELPHIA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announ
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Oct 03, 2025 8:15 PM GMT
PHILADELPHIA, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that